Printer Friendly

BIOPLASTY ANNOUNCES THIRD QUARTER RESULTS OF OPERATIONS

 BIOPLASTY ANNOUNCES THIRD QUARTER RESULTS OF OPERATIONS
 ST. PAUL, Minn., June 12 /PRNewswire/ -- Bioplasty, Inc.


(NASDAQ-NMS: BIOP) announced sales of $1,594,000 for the three months ended April 30, 1992, or a 54 percent decrease compared to the three months ended April 30, 1991. Operating loss for the three months ended April 30, 1992, was $3,028,000 compared to operating income of $575,000 for the three months ended April 30, 1991. Sales and operating loss for the nine months ended April 30, 1992, was $5,971,000 and $8,773,000 respectively, compared to sales of $8,983,000 and operating income of $1,363,000 for the nine months ended April 30, 1991.
 The company attributes the decreases in net revenues to the cessation of sales of MISTI silicone gel-filled and MISTI GOLD mammary prostheses in the United States and overseas markets, and to the credits granted to customers for returned breast implant product. Operating losses in fiscal 1992 have further resulted from the non-recurring charges associated with inventory write-downs totaling $1.4 million and various lawsuit costs and settlements totaling another $4.4 million.
 Worldwide sales of the company's wound care products are continuing, and upon submission of an IDE on MISTI GOLD Mammary Implants, the company will immediately request export approval for commercial distribution of the product to foreign markets. Upon approval by the FDA of the MISTI GOLD IDE, clinical studies will begin in the United States. The company also expects sales of Bioplastique and Macroplastique Macro Implants to resume in foreign markets. Such sales will be supplied from inventories manufactured in foreign locations.
 Bioplasty, Inc. has more than 20 years of experience in the development, manufacturing and marketing of plastic surgery products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol BIOP.
 BIOPLASTY, INC.
 SUMMARY OF OPERATIONS
 (In thousands, except per-share data)
 Three Months Ended Nine Months Ended
 4/30/92 4/30/91 4/30/92 4/30/91
 Net revenue $1,594 $3,463 $5,971 $8,983
 Operating income (loss) (3,028) 575 (8,773) 1,363
 Income tax expense (benefit) 210 170 (359) 359
 Net income (loss) $(3,254) $280 $(8,092) $845
 Earnings (loss) per share $(.81) $.08 $(2.01) $.26
 -0- 6/12/92
 /CONTACT: Timothy P. Lawin or Donald A. Major, 612-636-4112, both of Bioplasty/
 (BIOP) CO: Bioplasty, Inc. ST: Minneapolis IN: MTC SU: ERN


KH -- MN008 -- 9874 06/12/92 17:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 12, 1992
Words:414
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX -- CLOSING, FRIDAY, JUNE 12
Next Article:HIGHLAND SUPERSTORES REPORTS FIRST-QUARTER RESULTS
Topics:


Related Articles
BIOPLASTY, INC. ANNOUNCES FISCAL 1992 OPERATING RESULTS
BIOPLASTY ANNOUNCES FIRST QUARTER OPERATING RESULTS
BIOPLASTY ANNOUNCES STOCK DIVIDEND
BIO-MANUFACTURING ANNOUNCES 1991 EARNINGS
BIOPLASTY ANNOUNCES SECOND QUARTER RESULTS OF OPERATIONS
BIOPLASTY WITHDRAWS BREAST IMPLANTS OVERSEAS
BIOPLASTY ANNOUNCES APPROVAL OF MERGER WITH BIO-MANUFACTURING
BIOPLASTY, INC. ANNOUNCES SECOND QUARTER 1993 RESULTS OF OPERATIONS
BIOPLASTY, INC.; BIO-MANUFACTURING, INC.; AND UROPLASTY, INC. PROVIDES NOTICE OF BANKRUPTCY
BIOPLASTY ANNOUNCES EXTENSION OF RECORD DATE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters